- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01489670
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
February 13, 2014 updated by: Allergan
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
387
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zurich
-
Bülach, Zurich, Switzerland
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients diagnosed with primary open-angle glaucoma or ocular hypertension
Description
Inclusion Criteria:
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lumigan® 0.01%
Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
|
Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraocular Pressure (IOP) at Baseline
Time Frame: Baseline
|
IOP is a measurement of the fluid pressure inside the eye.
IOP was measured in the left and right eye at Baseline.
|
Baseline
|
Intraocular Pressure (IOP) at Week 12
Time Frame: Week 12
|
IOP is a measurement of the fluid pressure inside the eye.
IOP was measured in the left and right eye at the Final Visit at approximately Week 12.
The lower the IOP values the greater the improvement.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physician Evaluation of Efficacy Using a 5-Point Scale
Time Frame: Week 12
|
The physician evaluated efficacy using a 5-point scale (IOP lower than the target, Target IOP reached, IOP decreased but target not reached, IOP increased or No change).
The number of participants in each category is reported.
|
Week 12
|
Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale
Time Frame: Week 12
|
Patients evaluated their tolerability of treatment using a 4-point scale (very good, good, moderate, and poor).
The number of participants in each category is reported.
|
Week 12
|
Physician Evaluation of Tolerability of Treatment
Time Frame: Week 12
|
The physician evaluated the patient's tolerability of treatment using a 4-point scale (very good, good, moderate, and poor).
The percentage of participants assessed in each category is reported.
|
Week 12
|
Physician Reported Reasons for Early Discontinuation of Treatment
Time Frame: 12 Weeks
|
The number of patients who discontinued from treatment by category is reported.
More than one reason may apply to each patient.
|
12 Weeks
|
Number of Patients Continuing Treatment After 12 Weeks
Time Frame: Week 12
|
The number of patients continuing treatment after 12 weeks was determined by the physician answering yes to the question: Is the patient continuing on Lumigan® 0.01% treatment?
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
December 1, 2011
First Submitted That Met QC Criteria
December 8, 2011
First Posted (Estimate)
December 12, 2011
Study Record Updates
Last Update Posted (Estimate)
March 28, 2014
Last Update Submitted That Met QC Criteria
February 13, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MAF/AGN/OPH/GLA/032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on bimatoprost 0.01% ophthalmic solution
-
Amneal Pharmaceuticals, LLCCBCC Global Inc.; Amneal EU, LimitedNot yet recruitingOcular Hypertension | Open-angle GlaucomaUnited States
-
Amneal Pharmaceuticals, LLCCBCC Global ResearchRecruitingOcular Hypertension | Glaucoma, Open-AngleUnited States
-
Mankind Pharma LimitedCBCC Global ResearchCompleted
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | GlaucomaUnited States
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleAustria
-
AllerganCompletedLong-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionOcular Hypertension | GlaucomaSpain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
-
AllerganCompletedOcular Hypertension | Open-Angle GlaucomaBelgium
-
AllerganCompletedOcular Hypertension | Glaucoma, Open-AngleCanada, United States
-
Alcon ResearchCompletedOcular Hypertension | Glaucoma